偏头痛药物预防及治疗新进展  

Progress in drug prevention and treatment of migraine

作　　者：杨心怡 张菁[1] 李南洋 杨海静[1] 毛肖萌 YANG Xinyi;ZHANG Jing;LI Nanyang;YANG Haijing;MAO Xiaomeng(PhaseⅠUnit,Huashan Hospital,Fudan University,Shanghai 200040,China)

机构地区：[1]复旦大学附属华山医院I期临床研究室,上海200040

出　　处：《中国临床药理学与治疗学》2020年第12期1429-1435,共7页Chinese Journal of Clinical Pharmacology and Therapeutics

基　　金：“重大新药创制”科技重大专项(“十三五”)(2017ZX09304005)。

摘　　要：偏头痛是一种常见的神经内科疾病,严重影响生活质量,目前临床上的常用治疗药物尚不能满足临床需求。随着研究的不断深入,5-羟色胺1F受体激动剂、靶向作用于降钙素基因相关肽(CGRP)的药物等越来越多地被研发和上市。本文系统评估这些药物的作用机制、安全性及有效性、代谢特点等,为临床防治偏头痛提供更为科学的依据。Migraine is a common nervous system disease,which could seriously affect the quality of life.However,the medical treatment of migraine cannot meet the clinical needs at present.With the deepening of research,serotonin 1F receptor agonists and drugs targeting CGRP are more and more developed and marketed.In this paper,the mechanism of action,safety and efficacy,metabolic characteristics of these drugs were systematically evaluated to provide a more scientific basis for clinical prevention and treatment of migraine.

关 键 词：偏头痛 抗CGRP单克隆抗体 药代动力学 

分 类 号：R971[医药卫生—药品]